Pfister Neil T, Fomin Vitalay, Regunath Kausik, Zhou Jeffrey Y, Zhou Wen, Silwal-Pandit Laxmi, Freed-Pastor William A, Laptenko Oleg, Neo Suat Peng, Bargonetti Jill, Hoque Mainul, Tian Bin, Gunaratne Jayantha, Engebraaten Olav, Manley James L, Børresen-Dale Anne-Lise, Neilsen Paul M, Prives Carol
Department of Biological Sciences, Columbia University, New York, New York 10027, USA;
Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radiumhospital, 0310 Oslo, Norway; The K.G. Jebsen Center for Breast Cancer Research, Faculty of Medicine, Institute for Clinical Medicine, University of Oslo, 0450 Oslo, Norway;
Genes Dev. 2015 Jun 15;29(12):1298-315. doi: 10.1101/gad.263202.115. Epub 2015 Jun 16.
Mutant p53 impacts the expression of numerous genes at the level of transcription to mediate oncogenesis. We identified vascular endothelial growth factor receptor 2 (VEGFR2), the primary functional VEGF receptor that mediates endothelial cell vascularization, as a mutant p53 transcriptional target in multiple breast cancer cell lines. Up-regulation of VEGFR2 mediates the role of mutant p53 in increasing cellular growth in two-dimensional (2D) and three-dimensional (3D) culture conditions. Mutant p53 binds near the VEGFR2 promoter transcriptional start site and plays a role in maintaining an open conformation at that location. Relatedly, mutant p53 interacts with the SWI/SNF complex, which is required for remodeling the VEGFR2 promoter. By both querying individual genes regulated by mutant p53 and performing RNA sequencing, the results indicate that >40% of all mutant p53-regulated gene expression is mediated by SWI/SNF. We surmise that mutant p53 impacts transcription of VEGFR2 as well as myriad other genes by promoter remodeling through interaction with and likely regulation of the SWI/SNF chromatin remodeling complex. Therefore, not only might mutant p53-expressing tumors be susceptible to anti VEGF therapies, impacting SWI/SNF tumor suppressor function in mutant p53 tumors may also have therapeutic potential.
突变型p53在转录水平影响众多基因的表达,从而介导肿瘤发生。我们在多个乳腺癌细胞系中确定血管内皮生长因子受体2(VEGFR2),即介导内皮细胞血管生成的主要功能性VEGF受体,为突变型p53的转录靶点。VEGFR2的上调介导了突变型p53在二维(2D)和三维(3D)培养条件下促进细胞生长的作用。突变型p53在VEGFR2启动子转录起始位点附近结合,并在维持该位置的开放构象中发挥作用。相关地,突变型p53与SWI/SNF复合物相互作用,而该复合物是重塑VEGFR2启动子所必需的。通过查询由突变型p53调控的单个基因以及进行RNA测序,结果表明所有由突变型p53调控的基因表达中>40%是由SWI/SNF介导的。我们推测,突变型p53通过与SWI/SNF染色质重塑复合物相互作用并可能对其进行调控,从而通过启动子重塑影响VEGFR2以及众多其他基因的转录。因此,不仅表达突变型p53的肿瘤可能对抗VEGF治疗敏感,影响突变型p53肿瘤中SWI/SNF肿瘤抑制功能也可能具有治疗潜力。